[1] Bundesärztekammer (BÄK) KBK, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Chronische Herzinsuffizienz – Langfassung. Version 3 ed; 2019.
[2] BMBF. Würzburger Studie: Vorstufen einer Herzschwäche bei auffallend vielen jungen Menschen. 2020. https://www.gesundheitsforschung-bmbf.de/de/wurzburger-studie-vorstufen-einer-herzschwache-bei-auffallend-vielen-jungen-menschen-11615.php (accessed 15. August 2023).
[3] DGK. ESC Pocket Guidelines- Akute und chronische Herzinsuffizienz. Version 2021 ed; 2021.
[4] Heo S, Lennie TA, Okoli C, Moser DK. Quality of life in patients with heart failure: ask the patients. Heart Lung 2009; 38(2): 100-8.
[5] McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; 42(36): 3599-726.
[6] Graziani F, Varone F, Crea F, Richeldi L. Treating heart failure with preserved ejection fraction: learning from pulmonary fibrosis. Eur J Heart Fail 2018; 20(10): 1385-91.
[7] Vasan RS, Xanthakis V, Lyass A, et al. Epidemiology of Left Ventricular Systolic Dysfunction and Heart Failure in the Framingham Study: An Echocardiographic Study Over 3 Decades. JACC Cardiovasc Imaging 2018; 11(1): 1-11.
[8] McDonagh TA, Metra M, Adamo M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2023.
[9] Baldus S, Kacmaz K, Frey N, et al. Die Nationale Herz-Allianz – Update 2023. Die Kardiologie 2023; 17(2): 65-71.
[10] Kim SE, Yoo BS. Treatment Strategies of Improving Quality of Care in Patients With Heart Failure. Korean Circ J 2023; 53(5): 294-312.
[11] Deutsche Herzstiftung e.V.. Deutscher Herzbericht 2021. 2021.
[12] Leitlinien AdWMFASK. AWMF-Regelwerk „Leitlinien“. 2020.
[13] Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022; 145(18): e895-e1032.
[14] Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med 2021; 385(16): 1451-61.
[15] Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med 2022; 387(12): 1089-98.
[16] Jhund PS, Kondo T, Butt JH, et al. Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nat Med 2022; 28(9): 1956-64.
[17] Bhatt AS, Kosiborod MN, Vaduganathan M, et al. Effect of dapagliflozin on health status and quality of life across the spectrum of ejection fraction: Participant-level pooled analysis from the DAPA-HF and DELIVER trials. Eur J Heart Fail 2023; 25(7): 981-8.
[18] Anker SD, Usman MS, Anker MS, et al. Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension. Eur J Heart Fail 2023.
[19] Vardeny O, Fang JC, Desai AS, et al. Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial. Nat Med 2022; 28(12): 2504-11.
[20] Zaman S, Zaman SS, Scholtes T, et al. The mortality risk of deferring optimal medical therapy in heart failure: a systematic comparison against norms for surgical consent and patient information leaflets. Eur J Heart Fail 2017; 19(11): 1401-9.
[21] Shen L, Jhund PS, Docherty KF, et al. Accelerated and personalized therapy for heart failure with reduced ejection fraction. Eur Heart J 2022; 43(27): 2573-87.
[22] Savarese G, Kishi T, Vardeny O, et al. Heart Failure Drug Treatment-Inertia, Titration, and Discontinuation: A Multinational Observational Study (EVOLUTION HF). JACC Heart failure 2023; 11(1): 1-14.
[23] Girerd N, Von Hunolstein JJ, Pellicori P, et al. Therapeutic inertia in the pharmacological management of heart failure with reduced ejection fraction. ESC heart failure 2022; 9(4): 2063-9.
[24] Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. 2020; 383(15): 1436-46.
[25] Herrington WG, Staplin N, Wanner C, et al. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2023; 388(2): 117-27.
